Stocks · News reference
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Enliven Therapeutics, Inc. (ELVN)
Filed: 2026-10-14 AccNo: 0001193125-26-421761 Size: 160 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Enliven Therapeutics Announces FDA Alignment On Phase 3 Relcobatinib Chronic Myeloid Leukemia Trial Design, Expects Start Before Year-End
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70
Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $70.
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75